In this episode, 340B Report Publisher and CEO Ted Slafsky joins Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Luke Zarzecki in breaking down the latest in 340B news, including: Eli Lilly's move to cut off 340B pricing for certain hospitals; the Health Resources and Services Administration's (HRSA) efforts to implement another rebate pilot, the government's decision to not appeal a key hospital purchasing policy court ruling and recent 340B activity in the states.

Key Topics Covered:

Lilly Cuts Off Non-Compliant Hospital 340B Pricing

Shannon and Ted discuss Lilly's decision to end 340B pricing for certain hospitals that failed to comply with its 340B in-house pharmacy claims data requirements and how hospital trade groups responded to that move. Shannon notes that while 340B Health and the American Hospital Association urged HRSA to step in, the agency said it was still determining its "next steps." Luke talks about possible actions states may take in response to Lilly's actions and other drugmakers' in-house claims data requirements. And Will notes that Vermont recently updated its state 340B law to protect covered entities in response to manufacturer in-house policies.

HRSA Takes Another Step Towards Rebate Pilot

Will breaks down new HRSA regulatory documents and what they mean about a potential future 340B rebate pilot. He notes that HRSA is attempting to avoid the missteps that led federal courts to block the agency's original rebate pilot from taking effect. Will also explains that providers have disputed HRSA's estimate on the administrative burden of a rebate pilot, quoting a former HRSA official who argued it was "mind-boggling" that the agency hadn't changed its assessment.

Key State and Court Actions

Shannon breaks down HRSA's decision not to appeal a Washington, D.C. federal district court's ruling to strike down a controversial 13-year-old policy that restricted how certain 340B hospitals can purchase initial drug inventory. She notes that while hospitals celebrated the move and its implications, the agency could still pursue the issue through regulation—or more likely—federal guidance. Ted offers background on the group purchasing organization (GPO) prohibition and the significance of HRSA's ruling.

Will discusses a federal court ruling that allowed Washington state's 340B contract pharmacy access law to take effect this month. He also provides an update on Illinois' pair of 340B bills that are currently awaiting action from the state's governor.

July Panel on Key 340B Developments

Join Verity Solutions for a panel discussion just ahead of the 340B Coalition Summer Conference. The complimentary event will take place July 13 from 8 to 9:15 a.m. ET at the Gaylord National Resort in National Harbor, Maryland. The event is open to all and separate from the Coalition Conference, so you need to register in advance. Learn more and register here.

Subscribe & Stay Updated

How to Follow Us and Learn More About This Episode's Sponsor

Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.

Each episode is brought to you by one of our great Ultra Diamond sponsors, VytlOne. As the only independent provider of integrated pharmacy solutions, VytlOne leads the way in partnering with hospitals, health systems and health centers to unlock pharmacy revenue, strengthen local care and reinvest in communities. We are very grateful to VytlOne for its sponsorship.

Subscribe to 340B Report with a Special Discount

We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky joins Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Luke Zarzecki in breaking down the latest in 340B news, including: Eli Lilly's 340B in-house claims data threat and a leading provider law firm's response; high-stakes oral arguments over two states' contract pharmacy laws; and the results from primaries involving high-profile 340B advocates. The team also recaps 340B Report's recent webinar on key 340B legal issues.

Key Topics Covered:

Lilly's In-House Claims Data Ultimatum

Luke highlights two recent letters sent to the Health Resources and Services Administration: one from Lilly and one from Hall Render, a law firm representing 340B providers. Lilly notified covered entities they had five days to comply with its 340B in-house pharmacy claims data submission policy, while Hall Render called for a U.S. Department of Health and Human Services Inspector General investigation into Lilly's requirements. Shannon notes that Sanofi recently announced 340B in-house claims data requirements, making it the ninth drugmaker to do so.

Latest Primary Results

Shannon breaks down early results from June primary contests in California and South Dakota. She notes that U.S. Rep. Doris Matsui (D-Calif.), who is seen as a key 340B provider advocate in Congress, placed first in her primary. But, Shannon adds, she is likely to once again face off against a tough Democratic challenger, Mai Vang, in November. Shannon also discusses U.S. Rep. Dusty Johnson's (R-S.D.) third place finish in South Dakota's GOP gubernatorial primary, and how the loss of another key 340B leader on Capitol Hill could shape 340B policymaking in the next Congress.

Oral Arguments and 340B Report Webinar

Will discusses recent oral arguments on drugmaker challenges to Maine and Rhode Island's 340B contract pharmacy access laws before a Boston federal appeals court. He notes that one of the judges last year was a partner at a law firm where other partners were lobbying for a drug industry trade group against Maine's contract pharmacy bill before it became law. Will, Luke and Ted then break down the biggest takeaways from 340B Report's recent subscriber-only webinar, where two attorneys representing the covered entity and manufacturer perspectives joined 340B Report's editorial team to discuss the biggest 340B legal developments.

Subscribe & Stay Updated

How to Follow Us and Learn More About This Episode's Sponsor

Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.

Each episode is brought to you by one of our great Ultra Diamond sponsors, Pillr Health. Pillr is a leading provider of innovative solutions designed to optimize and streamline pharmacy operations with a focus on enhancing efficiency, reducing costs and improving patient outcomes, particularly within the 340B program. We are very grateful to Pillr Health for its sponsorship.

Subscribe to 340B Report with a Special Discount

We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky and Associate Editors and Senior Writers Shannon Young and Will Newton break down the latest in 340B news, including two high-profile 340B detractors' recent GOP U.S. Senate primary election losses, the newest member of a Senate bipartisan working group focused on 340B reform, a new dark money effort seeking to influence the 340B rebate debate and contract pharmacy access bills in Minnesota and Illinois. They also tease 340B Report's upcoming June 3 webinar.

Key Topics Covered:

Congressional Losses and an Addition Shannon breaks down U.S. Sen. Bill Cassidy (R-La.) and U.S. Rep. Earl "Buddy" Carter's (R-Ga.) recent GOP primary losses in two key Senate races and what the loss of the two high-profile 340B critics and advocates for change could mean for the program in the next Congress. Ted provides important historical context on Cassidy and Carter's legacies on 340B issues in Congress, as well as the losses and their highly consequential ramifications. Shannon also discusses U.S. Sen. John Boozman's (R-Ark.) addition to the "group of six" (G6) senators behind high-profile 340B program legislation, known as the "SUSTAIN 340B Act," including his record of supporting 340B providers in Congress.

Dark Money Campaign Emerges Will discusses his latest scoop on a new dark money effort pressuring congressional Republicans to support a 340B rebate model. He explains that an Austin, Texas-based nonprofit with undisclosed donors and ties to a Washington, D.C. lobbying firm recently launched a new advocacy campaign promoting 340B rebates. Will provides exclusive details on this effort and whether it will affect the ongoing 340B rebate debate.

State Updates and a 340B Report Webinar Will discusses Minnesota state legislators' failed effort to pass legislation to strengthen the state's existing 340B contract pharmacy law in the final days of the state session—despite it passing the state Senate and having bipartisan backers in the state House. He also discusses an ongoing battle over 340B contract pharmacy access legislation in Illinois.

Will then previews 340B Report's exclusive, subscriber-only webinar, which will take place June 3 at 1 p.m. ET. Attorneys representing the covered entity and drugmaker perspectives will join 340B Report's editorial team to break down ongoing litigation over state 340B contract pharmacy access laws, as well as potential new legal pathways for covered entities to challenge alleged overcharge violations. You can learn more about the webinar here.

Subscribe & Stay Updated

How to Follow Us and Learn More About This Episode's Sponsor

Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.

Each episode is brought to you by one of our great Ultra Diamond sponsors. Verity Solutions' innovative, award-winning 340B program management solutions are designed to optimize 340B pharmacy spend and maximize pharmacy supply chain savings. We are very grateful to Verity Solutions for its sponsorship.

Subscribe to 340B Report with a Special Discount

We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Luke Zarzecki break down the latest in 340B news, including recent congressional hearings and letters that focused on the 340B program, a major drug industry trade group's new seven-figure ad campaign targeting 340B hospitals and the Louisiana attorney general's moves to enforce the state's 340B contract pharmacy access law.

Key Topics Covered:

Congress Weighs In

Shannon breaks down two recent congressional hearings where the 340B program drew scrutiny from witnesses and lawmakers—a May 5 U.S. Senate Health, Education, Labor and Pensions (HELP) Committee field hearing in Louisiana and an April 28 U.S. House Ways and Means Committee hearing. She notes that U.S. Sen. Bill Cassidy (R-La.), who chairs the HELP Committee and faces a tough upcoming GOP primary challenge, did not say much about the 340B program at his panel's field hearing despite his investigation into the program and previous vocal calls for reform. However a witness, who leads a private cancer clinic, focused her attention on 340B and called for major changes. A Louisiana independent pharmacist also weighed in. Meanwhile, Will discusses competing congressional letters that supported and opposed federal efforts to implement a 340B rebate model. And Luke dives into an expected bipartisan bill that will exempt additional covered entities from rebates. He notes that while the bill has not been introduced yet, 340B Report got an exclusive look at its contents.

PhRMA Launches New Campaign

Shannon discusses the Pharmaceutical Research and Manufacturers of America's (PhRMA) newest seven-figure ad blitz that takes aim at 340B hospitals. She notes that the campaign, which follows a similar 2025 seven-figure effort from PhRMA, argues that "340B medicine markups are a goldmine for big hospital systems" and features a video ad depicting fictional hospital leaders at a "340B executive spa." Shannon also discusses how key hospital trade groups, including the American Hospital Association, responded to PhRMA's ad campaign.

Key Legal Developments

Will discusses the Louisiana attorney general's (AG) plans to take enforcement action against manufacturers for alleged violations of the state's 340B contract pharmacy access law. He notes that the move comes roughly three months after a three-judge panel for a New Orleans federal appeals court unanimously upheld the state law against multiple drugmaker legal challenges. And it came as the AG said she's received numerous complaints about alleged violations of the law. Will explains that Louisiana was the second state in the nation to enact a contract pharmacy law, following Arkansas, which similarly took enforcement action following a legal victory.

Subscribe & Stay Updated

How to Follow Us and Learn More About This Episode's Sponsor

Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.

Each episode is brought to you by one of our great Ultra Diamond sponsors. NuvemRx empowers covered entities to turn 340B from a compliance burden into a strategic asset with a full suite of TPA, in-house pharmacy and referral solutions. Learn more at www.nuvemrx.com. We are very grateful to NuvemRx for its sponsorship.

Subscribe to 340B Report with a Special Discount

We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Luke Zarzecki break down the latest in 340B news, including the comments submitted to the Health Resources and Services Administration (HRSA) in response to the agency's 340B rebate request for information (RFI); what Congress and Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. had to say about 340B rebates and the program, in general; and key legal developments with major 340B implications.

Key Topics Covered:

Rebate RFI Wraps Up

Will breaks down the avalanche of responses to HRSA's RFI seeking comments on whether to implement a future 340B rebate model leading up to the agency's April 20 deadline. He notes that the submissions came against the backdrop of federal court rulings that blocked HRSA's initial 340B rebate pilot proposal from taking effect Jan. 1, as many providers and manufacturers were likely writing their comments anticipating a potential future legal challenge if HRSA attempts to implement a new rebate model.

Congress and Kennedy on Rebates

Luke and Will discuss competing letters circulating in Congress relating to a potential federal 340B rebate model. Shannon discusses what appeared to be Kennedy's first public comments on 340B rebates, which came during a series of Capitol Hill appearances he made on the Trump administration's fiscal year 2027 HHS budget proposal. Shannon also highlights the secretary's criticism of how some 340B hospitals use program savings, as well as praise he shared for the program while fielding lawmakers' questions. Luke talks about a Senate committee hearing on drug pricing at which a witness pushed to end the 340B program's current structure and replace it with a direct subsidy program.

Key Legal Developments

Will breaks down a Richmond, Va.-based federal appeals court's 2-1 decision against Maryland's 340B contract pharmacy access law. He notes that the same three judges on the Maryland case also recently decided against West Virginia's similar 340B contract pharmacy access law. Will explains that those two decisions were the first appellate rulings to side with manufacturers, after three-judge federal appeals court panels unanimously upheld similar laws in Arkansas, Louisiana and Mississippi. Ted and Will also discuss whether the appeals court will grant West Virginia officials' recent request for a full panel rehearing.

Subscribe & Stay Updated

How to Follow Us and Learn More About This Episode's Sponsor

Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.

Each episode is brought to you by one of our great Ultra Diamond sponsors. Visante partners with health systems to deliver confidence in 340B—through deep experience, rigorous compliance and relentless focus on program compliance. We are very grateful to Visante for its sponsorship.

Subscribe to 340B Report with a Special Discount

We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Luke Zarzecki break down the latest in 340B news, including the wave of identical responses to the Health Resources and Services Administration's (HRSA) 340B rebate request for information (RFI), the Trump Administration's renewed proposal to shift oversight of the 340B program to another federal agency and key legal developments with major 340B implications.

Key Topics Covered:

Duplicate 340B Rebate RFI Responses

Will breaks down early stakeholder responses to the HRSA's 340B rebate RFI, which the agency issued just days after withdrawing its previous 340B rebate pilot. He notes that more than half of the initial responses were identical submissions closely mirroring a template from Patients Rising, a patient group that lists more than a dozen large drugmakers among its corporate sponsors. Will notes that hours after 340B Report broke news on the submissions, Patients Rising said it was ending work with the third-party firm it hired for RFI outreach.

Trump's New Budget and Tariffs

Shannon discusses the Trump administration's proposed fiscal year (FY) 2027 Health and Human Services Department budget and what it means for the 340B program. She notes that the HHS spending proposal revives previous plans to restructure HRSA and move the 340B program to the Centers for Medicare and Medicaid Services, as well as calls for a major increase in 340B funding. Luke offers insights into how Congress could approach FY 27 funding legislation—including an effort to attach language barring a 340B rebate model. Luke also breaks down the White House's latest plans to implement tariffs on pharmaceutical products.

Key Legal Developments

Shannon discusses the implications of a recent Washington, D.C. federal district court ruling that struck down a 2013 HRSA policy that restricts how certain 340B hospitals can purchase initial drug inventory. Will breaks down drugmaker AbbVie's new lawsuit challenging HRSA's 340B patient definition, including the history of the agency's definition and what the legal outcome could mean for the 340B program's future.

Subscribe & Stay Updated

How to Follow Us and Learn More About This Episode's Sponsor

Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.

Each episode is brought to you by one of our great Ultra Diamond sponsors. PharmaForce is the only third party administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. Learn more at www.thepharmaforce.com. We are very grateful to PharmaForce for its sponsorship.

Subscribe to 340B Report with a Special Discount

We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and 340B Report's national correspondent Luke Zarzecki break down the latest in 340B news, including 340B stakeholder reactions to a provider hearing in the U.S. House and ongoing discussion over a 2027 fiscal year (FY) federal spending package that could include language blocking 340B rebates. The team also discusses major updates in the states, including a newly enacted first-of-its-kind 340B law in the Pacific Northwest, a controversial effort to kill a 340B bill in the Midwest and a closer look into state prescription drug affordability boards (PDABs).

Key Topics Covered:

Capitol Hill Update

Shannon and Luke discuss a recent House Energy & Commerce (E&C) Health Subcommittee hearing on providers' role in health care costs, which focused on the 340B program, among other things. Shannon breaks down what two of the witnesses had to say about the drug discount program. Luke highlights the questions key lawmakers asked witnesses, as well as how two senior Republican committee members called for 340B reforms and support for their 340B ACCESS Act, which has drawn major pushback from provider groups. Shannon also offers an update on the FY 2027 federal appropriations process taking shape on Capitol Hill, noting that a group of bipartisan House lawmakers is pushing to add language to the health spending bill that would block a 340B rebate model's implementation.

Key State Developments

Will discusses "the tale of two states," where high-profile 340B bills in Washington and Kansas faced very different outcomes. He also discusses two recent federal district court rulings in favor of state contract pharmacy laws, which continued a string of mostly favorable legal rulings for the states.

Deep Dive into PDABs

Luke discusses PDABs that are popping up across the states and their potential implications on the 340B program. At least 11 states have created a PDAB or a similar board tasked with addressing high drug prices, with some states granting that board to set upper payment limits on drugs. Luke shares why experts say PDABs could lead to lower 340B savings for covered entities, as well as other impacts on the drug supply chain.

Subscribe & Stay Updated

How to Follow Us and Learn More About This Episode's Sponsor

Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.

Each episode is brought to you by one of our great Ultra Diamond sponsors. Proximity is the 340B revenue operations platform built to bring control back to your program. Proximity unifies and normalizes TPA, pharmacy, EHR, wholesaler and payer data into a single system—so issues can be identified, corrected and resolved across the full claim lifecycle. To learn more, reach out to [email protected]. We are very grateful to Proximity for its sponsorship.

Subscribe to 340B Report with a Special Discount

We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and 340B Report's national correspondent Luke Zarzecki break down the latest in 340B news, including a key U.S. House subcommittee's upcoming provider hearing and a leadership shakeup that could affect the bipartisan U.S. Senate 340B working group. The team also discusses reactions to another major drugmaker's plan to require 340B in-house pharmacy data reporting, major 340B related-developments in two federal court cases and divergent state 340B program bills on the cusp of becoming law.

Key Topics Covered:

Capitol Hill Update

Shannon and Luke discuss the latest 340B developments on Capitol Hill. Shannon previews the House Energy and Commerce (E&C) Health Subcommittee's March 18 hearing that will look at the role providers play in rising health care costs. She notes that while the hearing will not specifically focus on the 340B program, the issue is likely to arise with the American Hospital Association—which successfully blocked the Trump administration's 340B rebate pilot from taking effect—among those slated to testify. Shannon also highlights E&C Committee Chairman Brett Guthrie's (R-Ky.) reintroduction of a bill, which calls for a study of how value-based purchasing arrangements affect the 340B program. Luke talks about what the change in guard at the Department of Homeland Security could mean for the bipartisan 340B Senate working group, after President Donald Trump nominated U.S. Sen. Markwayne Mullin (R-Okla.) to take over for DHS Secretary Kristi Noem.

Claims Data Pushback

Will discusses Novo Nordisk's recent announcement that it plans to require covered entities to submit claims data for 340B utilization at in-house pharmacies in order to access 340B pricing. He explains why Novo's policy, which is similar to one Eli Lilly announced earlier this year, marks a significant expansion of reporting requirements. Meanwhile, Luke breaks down what provider groups and pharmaceutical stakeholders have said about the new requirements, and the actions they have taken in response to them.

Key Court Rulings

Shannon, Will and Ted discuss two recent federal court rulings that have major 340B implications. Shannon shares how a Washington D.C. federal district court's order striking down the Health Resources and Services Administration's (HRSA) contentious 340B hospital offsite clinic registration policy is a major win for hospitals. Ted provides historical context on the case and why hospitals sued HRSA over the policy. Will discusses the federal government's latest amicus briefs backing drugmakers in legal challenges to state 340B contract pharmacy access laws, and how the unexpected move could potentially impact ongoing litigation.

State Legislative Activity

Will discusses Washington's state 340B contract pharmacy access legislation, which also includes both provider and drugmaker reporting requirements, that's awaiting action from Gov. Bob Ferguson (D). He also dives into Virginia's unsuccessful efforts to pass contract pharmacy access legislation after lawmakers amended an earlier contract pharmacy bill to replace it with a work study group. Ted explains why he was surprised that Virginia did not enact a 340B contract pharmacy access law despite early momentum in the state capitol and a newly elected governor who has been a longtime 340B advocate.

Subscribe & Stay Updated

How to Follow Us and Learn More About This Episode's Sponsor

Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.

Each episode is brought to you by one of our great Ultra Diamond sponsors. This week's episode is sponsored by CompassRx, the premier AI services platform built exclusively for 340B. Harnessing pharmacy and AI expertise, CompassRx helps maximize 340B savings and operational efficiency. Visit CompassRx.com to learn more. We are very grateful to CompassRx for its sponsorship.

Subscribe to 340B Report with a Special Discount

We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and Luke Zarzecki, 340B Report's national correspondent, break down the latest in 340B news, including the Trump administration's high-profile entrance into the fight over state 340B contract pharmacy access laws. The team also discusses updates in the federal government's consideration of a potential new 340B rebate pilot, President Donald Trump's recent calls to codify most-favored nation (MFN) pricing agreements and the 340B Coalition's winter conference and National Association of Community Health Centers' (NACHC) Policy & Issues Forum.

Key Topics Covered:

Contract Pharmacy Restrictions Fight Heats Up

Will discusses the Trump administration's unexpected move to file amicus briefs supporting two drugmaker legal challenges to state 340B contract pharmacy access laws in Colorado and Rhode Island. He explains that most federal court rulings on contract pharmacy access laws have sided with the states, noting it is unclear to what extent the federal government's briefs will affect this trend. Will also notes that two U.S. Justice Department lawyers who signed the briefs previously represented drugmakers in drug pricing litigation, including one who served as a drugmaker's counsel in cases on 340B contract pharmacy use and 340B rebates.

Rebate Model Update

Luke, Shannon and Will discuss the latest developments in the federal government's consideration of a potential new 340B rebate model after court action halted the initial pilot from taking effect. They break down the latest regulatory actions surrounding that effort, including the White House's Office of Management and Budget's review of a prerule and the Health Resources and Services Administration's (HRSA) subsequent issuance of a request for information and an information collection request—and how stakeholders have responded to them. Will offers insights into what HRSA's possible new rebate model could look like based off of these documents.

MFN Codification Push

Shannon highlights the Trump administration's recent push to codify MFN principles into federal law, including the president's State of Union call for Congress to pass such legislation and Centers for Medicare and Medicaid Services Administrator Mehmet Oz's similar comments during a Pharmaceutical Research and Manufacturers of America (PhRMA) forum. She notes pushback such efforts have garnered from PhRMA, which has instead urged lawmakers to focus on reforming pharmacy benefit managers and the 340B program.

Conference Recaps

Will shares his key takeaways from the Winter 340B Coalition Conference in San Diego, including provider concerns with manufacturer actions they argue are threatening the 340B program. He also discusses health policy experts' takes on the program, including what to expect from Congress and the Trump administration in the coming months. Luke discusses HRSA Administrator Tom Engels' comments at NACHC's forum.

Subscribe & Stay Updated

How to Follow Us and Learn More About This Episode's Sponsor

Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.

Each episode is brought to you by one of our great Ultra Diamond sponsors. This episode is sponsored by RxParadigm. RxParadigm's mission is to cultivate innovative approaches and technologies that promote transparency and authenticity, leading to enhanced outcomes, reduced overall healthcare costs and effective 340B program administration. We are very grateful to RxParadigm for its sponsorship.

Subscribe to 340B Report with a Special Discount

We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky, Associate Editors and Senior Writers Shannon Young and Will Newton and Luke Zarzecki, 340B Report's new national correspondent, break down the latest in 340B news, including 340B legislative developments on Capitol Hill and statehouses—and the role of dark money campaigns trying to shape the message. The team also discusses the Health Resources and Services Administration's major decision to formally withdraw its 340B rebate model pilot and what that could mean for the future of drugmaker-backed efforts to pursue 340B rebates. Key Topics Covered:

Capitol Hill Happenings Shannon, Luke and Will highlight the latest 340B-related happenings in Congress. Shannon discusses a new bipartisan U.S. House bill that aims to prevent federally qualified health centers from being included in any 340B rebate models and previews a yet-to-be introduced bill that would expand similar protections to other 340B covered entities, but not major hospitals. Luke provides an update on the bipartisan U.S. Senate group working on the SUSTAIN 340B Act, including what the final legislation could look like and the reported issues stalling its introduction. Shannon also offers a recap of the recently enacted federal spending package and how it's expected to affect 340B stakeholders. Meanwhile, Will discusses Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy's (R-La.) recent inquiries into 340B prime vendor Apexus as part of his broader probe into the 340B program.

Rebate Model Update Will discusses the federal government's recent filing formally withdrawing its controversial 340B rebate pilot proposal and agreeing to new procedural guardrails if it attempts to implement a different 340B rebate model in the future. He then details the hospital lawsuit that led federal courts to block implementation of the 340B rebate pilot before it took effect on Jan. 1. Will also discusses what the outcome of this litigation could mean for the future of 340B rebates.

States Eye 340B Bills Will shares new developments from statehouses in Illinois, Michigan, Kansas and Virginia, where lawmakers are considering 340B contract pharmacy access legislation, 340B provider reporting bills—or both. He also breaks down 340B Report's recent coverage of the tactics of new dark multiple new money efforts opposing 340B contract pharmacy legislation in multiple states.

Subscribe & Stay Updated

How to Follow Us and Learn More About This Episode's Sponsor

Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.

Each episode is brought to you by one of our great Ultra Diamond sponsors. This episode is sponsored by VytlOne. As the only independent provider of integrated pharmacy solutions, VytlOne leads the way in partnering with hospitals, health systems and health centers to unlock pharmacy revenue, strengthen local care, and reinvest in communities. We are very grateful to VytlOne for its sponsorship.

Subscribe to 340B Report with a Special Discount

We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.